Wordt geladen...
Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone
Base excision repair (BER) is an essential pathway for pancreatic ductal adenocarcinoma (PDA) survival. Attempts to target this repair pathway have failed due to lack of tumor-selectivity and very limited efficacy. The NAD(P)H:Quinone Oxidoreductase 1 (NQO1) bioactivatable drug, ß-lapachone (ARQ761...
Bewaard in:
| Gepubliceerd in: | Sci Rep |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Publishing Group
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4658501/ https://ncbi.nlm.nih.gov/pubmed/26602448 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep17066 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|